Abstract
Background/aims: Data comparing the antibody responses of different coronavirus disease 2019 (COVID-19) vaccine platforms according to dose with natural severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection-induced antibody responses are limited.
Methods: Blood samples from adult patients with mild and severe COVID-19 and healthcare workers who received ChAdOx1 nCoV-19 vaccine (2nd dose at 12-week intervals) and BNT162b2 vaccine (2nd dose at 3-week intervals) were collected and compared by immunoglobulin G immune responses to SARS-CoV-2 specific spike protein using an in-house-developed enzyme-linked immunosorbent assay.
Results: A total of 53 patients, including 12 and 41 with mild and severe COVID-19, respectively, were analyzed. In addition, a total of 73 healthcare workers, including 37 who received ChAdOx1 nCoV-19 and 36 who received BNT162b2, were enrolled. Antibody responses after the first and second doses of the ChAdOx1 nCoV-19 vaccine or the first dose of the BNT162b2 vaccine were similar to those in convalescent patients with mild COVID-19, but lower than those in convalescent patients with severe COVID-19, respectively. However, after the second dose of the BNT162b2 vaccine, the antibody response was comparable to that in convalescent patients with severe COVID-19.
Conclusion: Our data suggest that the second dose of mRNA vaccination may be more beneficial in terms of long-term immunity and prevention of SARS-CoV-2 variant infection than a single dose of COVID-19 vaccination or homologous second challenge ChAdOx1 nCoV-19.
Keywords: Antibody formation; SARS-CoV-2; Vaccines.
【저자키워드】 SARS-CoV-2, Vaccines., antibody formation, 【초록키워드】 COVID-19, coronavirus disease, mRNA vaccination, Coronavirus disease 2019, BNT162b2 vaccine, immune response, severe COVID-19, Immunity, Antibody Response, SARS-CoV-2 variant, Infection, healthcare worker, Spike protein, BNT162b2, enzyme-linked immunosorbent assay, Antibody responses, Convalescent patients, Immunoglobulin G, COVID-19 vaccination, Immunoglobulin, immune responses, healthcare, Patient, Mild, vaccine platform, homologous, ChAdOx1, patients, ChAdOx1 nCoV-19, convalescent patient, single dose, ChAdOx1 nCoV-19 vaccine, antibody formation, Coronavirus-2, dose, acute respiratory syndrome, acute respiratory syndrome coronavirus, Blood samples, second dose, enzyme, Adult patients, first dose, acute respiratory syndrome coronavirus-2, blood sample, intervals, enzyme-linked immunosorbent, enrolled, analyzed, collected, addition, comparable, the antibody response, 【제목키워드】 COVID-19 vaccine, Patient, Mild, dose,